Coreline Soft inks China MOU with Suhai to expand AI imaging presence in Asia

Korea's Coreline Soft has signed a memorandum of understanding with China’s Jiangsu Suhai Information Technology to advance co-development of AI-driven imaging technologies and strengthen clinical and commercial ties across Asia, the Korean company announced Monday.

The agreement marks a renewed push into the Chinese market for Coreline Soft, following earlier deployments of its AVIEW chronic obstructive pulmonary disease (COPD) solution—which uses AI to analyze lung CT scans and quantify disease indicators such as emphysema, airway wall thickness, and air trapping—in hospitals including Ningxia Medical University and Shanghai Changzheng Hospital. 

The deal also completes what Coreline calls a strategic “axis” connecting Taiwan, Japan, and China in its Asia expansion strategy.

Coreline Soft previously secured contracts with Taiwanese institutions such as National Taiwan University Hospital and has partnered with fellow Korean AI firm VUNO to enter the Japanese market.

Coreline Soft said Suhai operates a wide hospital network and has built an AI-powered data infrastructure, positioning it as a key player in China’s fast-growing medical AI sector. 

According to Coreline, Suhai has secured multiple national clinical research projects focused on lung disease and maintains a large repository of imaging data that will help localize and validate Coreline’s products in the Chinese market.

China’s medical AI industry was valued at 38.8 billion yuan (approximately $5.32 billion) in 2021 and is projected to grow more than 48 percent annually through 2027, according to market research firm Graphical Research.

“China is the world’s largest market for lung disease, and the government is actively promoting AI adoption in healthcare,” said Coreline CEO Kim Jin-kook in a statement. “This partnership is key to expanding our footprint in Asia and complements our presence in Europe and the U.S.”

Kim added that navigating China’s complex regulatory environment requires local expertise, making Suhai a strategic partner for accelerating regional deployment.

Suhai CEO Wang Ping pointed to surging demand for AI-based early diagnosis tools, especially those using low-dose CT for chronic diseases such as cardiovascular disease, COPD, cancer, and diabetes. He noted that Coreline Soft’s AVIEW platform—covering lung nodule analysis, COPD, and coronary artery calcium scoring—is among the most advanced globally and will serve as a core solution in upcoming joint clinical decision support system (CDSS) projects.